Cellular therapies for spinal cord injury: What will the FDA need to approve moving from the laboratory to the human?

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The transplantation of living cells and tissues to restore function and/or provide therapeutic molecules has been an active and ongoing area of research interest for over 25 years. Several of these potential therapies have reached initial clinical trials, and it is likely that applications will continue to expand, and that novel and improved approaches will be explored over the next several years. In the past, many of these experimental approaches were tested in early clinical trials without the oversight of regulatory agencies such as the Food and Drug Administration. However, as novel cellular therapies move from preclinical laboratory findings to the clinical arena, researchers and regulators face new and continually evolving issues and uncertainties involving long-term safety and efficacy. Using adrenal medullary transplantation in the spinal cord for pain as an example, this review presents an overview of past and current regulatory guidelines for moving these promising, novel cellular transplantation therapies from the laboratory to the human.

Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalJournal of Rehabilitation Research and Development
Volume40
Issue number4 SUPPL. 1
StatePublished - Jul 1 2003

Fingerprint

Spinal Cord Injuries
Transplantation
Cells
Clinical Trials
Tissue
Tissue Transplantation
Molecules
Cell Transplantation
United States Food and Drug Administration
Therapeutics
Uncertainty
Spinal Cord
Research Personnel
Guidelines
Safety
Pain
Research

Keywords

  • Cell transplantation
  • Center for Biologics Evaluation and Research (CBER)
  • Chromaffin cells
  • Food and Drug Administration (FDA)
  • Pain
  • Regulatory agencies
  • Spinal cord injury

ASJC Scopus subject areas

  • Rehabilitation
  • Health Professions(all)
  • Engineering(all)

Cite this

@article{9a23d5c23c694559ad18fb8bc4daf757,
title = "Cellular therapies for spinal cord injury: What will the FDA need to approve moving from the laboratory to the human?",
abstract = "The transplantation of living cells and tissues to restore function and/or provide therapeutic molecules has been an active and ongoing area of research interest for over 25 years. Several of these potential therapies have reached initial clinical trials, and it is likely that applications will continue to expand, and that novel and improved approaches will be explored over the next several years. In the past, many of these experimental approaches were tested in early clinical trials without the oversight of regulatory agencies such as the Food and Drug Administration. However, as novel cellular therapies move from preclinical laboratory findings to the clinical arena, researchers and regulators face new and continually evolving issues and uncertainties involving long-term safety and efficacy. Using adrenal medullary transplantation in the spinal cord for pain as an example, this review presents an overview of past and current regulatory guidelines for moving these promising, novel cellular transplantation therapies from the laboratory to the human.",
keywords = "Cell transplantation, Center for Biologics Evaluation and Research (CBER), Chromaffin cells, Food and Drug Administration (FDA), Pain, Regulatory agencies, Spinal cord injury",
author = "Jacqueline Sagen",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "40",
pages = "71--79",
journal = "Journal of rehabilitation R&D",
issn = "0748-7711",
publisher = "Rehabilitation Research and Development Service",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Cellular therapies for spinal cord injury

T2 - What will the FDA need to approve moving from the laboratory to the human?

AU - Sagen, Jacqueline

PY - 2003/7/1

Y1 - 2003/7/1

N2 - The transplantation of living cells and tissues to restore function and/or provide therapeutic molecules has been an active and ongoing area of research interest for over 25 years. Several of these potential therapies have reached initial clinical trials, and it is likely that applications will continue to expand, and that novel and improved approaches will be explored over the next several years. In the past, many of these experimental approaches were tested in early clinical trials without the oversight of regulatory agencies such as the Food and Drug Administration. However, as novel cellular therapies move from preclinical laboratory findings to the clinical arena, researchers and regulators face new and continually evolving issues and uncertainties involving long-term safety and efficacy. Using adrenal medullary transplantation in the spinal cord for pain as an example, this review presents an overview of past and current regulatory guidelines for moving these promising, novel cellular transplantation therapies from the laboratory to the human.

AB - The transplantation of living cells and tissues to restore function and/or provide therapeutic molecules has been an active and ongoing area of research interest for over 25 years. Several of these potential therapies have reached initial clinical trials, and it is likely that applications will continue to expand, and that novel and improved approaches will be explored over the next several years. In the past, many of these experimental approaches were tested in early clinical trials without the oversight of regulatory agencies such as the Food and Drug Administration. However, as novel cellular therapies move from preclinical laboratory findings to the clinical arena, researchers and regulators face new and continually evolving issues and uncertainties involving long-term safety and efficacy. Using adrenal medullary transplantation in the spinal cord for pain as an example, this review presents an overview of past and current regulatory guidelines for moving these promising, novel cellular transplantation therapies from the laboratory to the human.

KW - Cell transplantation

KW - Center for Biologics Evaluation and Research (CBER)

KW - Chromaffin cells

KW - Food and Drug Administration (FDA)

KW - Pain

KW - Regulatory agencies

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=0043233331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043233331&partnerID=8YFLogxK

M3 - Article

C2 - 15077651

AN - SCOPUS:0043233331

VL - 40

SP - 71

EP - 79

JO - Journal of rehabilitation R&D

JF - Journal of rehabilitation R&D

SN - 0748-7711

IS - 4 SUPPL. 1

ER -